ArticleEplasty2025
Case Series of Reconstruction Applying NovoSorb Biodegradable Temporising Matrix: Preliminary Practice and Findings in the United Kingdom.
Article in Eplasty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Biodegradable Temporizing Matrix for Facial Reconstruction Following Mohs Micrographic Surgery: A Multi-Subunit Analysis.Bioengineering (Basel, Switzerland) · 2026Article
- Biodegradable temporizing matrix (BTM): A valuable reconstructive adjunct.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biodegradable temporizing matrix (BTM) is a novel synthetic dermal matrix for wound reconstruction and an alternative to biological dermal substitutes such as Integra (Integra LifeSciences). It provides a scaffold for dermal regeneration and acts as a temporizing device prior to skin graft application, reducing the need for autologous tissue donor sites such as local or free-flap transfer. Methods: This retrospective case series involved 12 patients whose surgery was completed with BTM from October 2021 to February 2023. The inpatient stay, subsequent procedures, and any complications were also reviewed. Results: The median time for inpatient stay was 3.5 days, and patients who required skin grafts after full BTM integration were treated as a day case. Only 1 case had the complication of postoperative infection. Conclusions: The study supports the application of BTM products to heal wounds with exposed bone or tendon. This is considered a low-risk option to reduce complications and improve reconstructive and cosmetic outcomes, particularly in the head and neck region.
Indexed as
Identifiers
40661099PMC12257962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.